BioInvent International (BINV) Corporate presentation summary

Strategic focus and pipeline overview

• Developing first-in-class immune-modulating antibodies for cancer, with four ongoing clinical programs and a strong financial position funded through Q1 2027.

• Core strengths include a validated target discovery platform, in-house GMP manufacturing, and a world-class scientific team.

• Listed on NASDAQ OMX Stockholm MidCap with a robust international investor base.

BI-1808 in ovarian cancer

• BI-1808 targets TNFR2, depleting Tregs and activating macrophages to induce CD8+ T cell antitumor immunity.

• Demonstrated single-agent activity in heavily pre-treated solid tumor patients, including a complete response in ovarian cancer.

• Combination with pembrolizumab achieved a 24% ORR and 56% DCR in recurrent ovarian cancer, with mPFS of 10.3 months.

• Late, durable responses observed, consistent with immunotherapy mechanisms.

• Triplet regimen with pembrolizumab and paclitaxel to be initiated Q4 2026, aiming to surpass current standards.

BI-1808 in CTCL and PTCL

• BI-1808 shows promising efficacy in cutaneous and peripheral T-cell lymphoma, with 50% ORR and 75% DCR in CTCL combination therapy.

• Higher efficacy in mycosis fungoides (MF) than most competitors, with best-in-class tolerability and only 4% discontinuation.

• Orphan Drug and Fast Track designations granted for TCL and CTCL.